- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05908877
Cardio-Metabolic Risk Evaluation in Overweight and Obese Children (CardMetSOb)
Complex Assessment and Monitoring of Cardio-metabolic Risk in Overweight and Obese Children
Metabolic and cardio-vascular complications can often appear in overweight and obese children from an early age. Currently, there are few studies in the specialized literature that correlate clinical, biological and ultrasound parameters in order to stratify cardio-metabolic risk in obese children. Also, the specialized literature is poor regarding longitudinal follow-up and the importance of diet for reducing metabolic and cardiovascular complications in these children.
This study is designed to assess the hypothesis that the sustained improvement of lifestyle with regard to nutrition and exercise can reverse cardiometabolic multimorbidities in obese children as assessed by clinical, biological and ultrasound evaluation.
Study Overview
Status
Conditions
Intervention / Treatment
- Other: History and Clinical evaluation
- Diagnostic test: Biological evaluation of the metabolic syndrome and components
- Diagnostic test: Ultrasound evaluation of subclinical atherosclerosis and visceral fat storage
- Other: Nutritional assessment
- Behavioral: Psychological evaluation of the impact of obesity/overweight
Detailed Description
The Metabolic Syndrome (MetS) is a group of metabolic conditions that increase the risk of cardiovascular events, insulin resistance and type 2 diabetes. Obesity is often the first stage in the subsequent development of MetS. Further, one or more changes may occur, such as: an increase in triglycerides, low-density lipoprotein cholesterol (LDL-C), insulin resistance and blood pressure, respectively a decrease in high-density lipoprotein cholesterol (HDL-C) and glucose tolerance.
The term "nonalcoholic fatty liver disease" (NAFLD) refers to a spectrum of conditions ranging from steatosis to nonalcoholic steatohepatitis (NASH) and fibrosis rather than a single entity. The main risk factors are obesity and the metabolic dysregulations that it causes. Obesity contributes to the development of NAFLD because it not only leads to metabolic imbalance but also increases oxidative stress and mitochondrial dysfunction.
An early indication of metabolic and cardiovascular subclinical disease, is represented by an increase of the carotid intima-media thickness (CIMT), of subcutaneous and visceral adipose tissue, as well as the fatty liver deposition. B-mode ultrasound allows measuring of all these parameters thereby contributing to the early detection of changes at these levels.
The ever-increasing incidence of pediatric obesity, enhanced by the recent coronavirus (COVID-19) pandemic, imposes the need for clinical, paraclinical-imaging, biological, nutritional and psychological evaluation and monitoring of this population.
The study aims to develop an algorithm for the complex assessment of cardio-metabolic risk in overweight and obese children on the one hand, as well as to reduce this risk by establishing a nutrition and physical activity plan simultaneously with a continuous monitoring of the results obtained following this plan, on the other side.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Teofana O Bizerea-Moga, MD PhD
- Phone Number: +40729093725
- Email: bizerea.teofana@umft.ro
Study Contact Backup
- Name: Cornel Musei
- Email: neoped.medica@gmail.com
Study Locations
-
-
Timiş
-
Timişoara, Timiş, Romania, 300425
- Neoped - Centru de Pediatrie
-
Contact:
- Teofana O Bizerea-Moga, MD PhD
- Phone Number: +40729093725
- Email: bizerea.teofana@umft.ro
-
Contact:
- Cornel Musei
- Email: neoped.medica@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- clinical diagnosis of overweight or obesity
- informed consent of caregivers
Exclusion Criteria:
- lean/normal weight subjects
- monogenic or syndromic obesity
- endocrine obesity (e.g., hypothyroidism, Cushing's syndrome)
- medication-induced obesity
- associated chronic diseases (other than components of the metabolic syndrome)
- lack of informed consent of caregivers
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Overweight and Obese Children
Children diagnosed as overweight or obese, defined by the Centers for Disease Control and Prevention (CDC) as a BMI between the 85th and 95th percentile, or above the 95th percentile for the same age and sex, respectively.
|
HISTORY and CLINICAL EVALUATION and recording of the following parameters:
LABORATORY INVESTIGATIONS will include:
ULTRASOUND EVALUATION by:
NUTRITION CONSULT Initial consult will include: food habits survey aiming at identifying the nutritional factors that led to an increased Body Mass Index (BMI) and recommendations At reevaluations the food diary of the patients will be evaluated and recommendations will be adapted accordingly. The final visit will include evaluation of the food diary looking to identify the factors that have or have not helped to normalize BMI in order to recommend a long-term healthy lifestyle. PSYCHOLOGICAL ASSESSMENT by: Evaluation of pediatric health-related quality of life will be assessed with Pediatric Quality of Life Inventory (PedsQL). The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life. Another questionnaire that will be used is the the Rosenberg Self-Esteem Scale. It is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree. A higher score means higher self-esteem. Drawing in children is a communicative tool, many times more than reading or language. It can measure the image of the self and the image of the others and is representative of the unconscious. Questionnaires and drawing interpretation will be done at the initial presentation and at every control visit. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from Baseline Body Mass Index in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial measurement of the body mass index (BMI) followed by three additional measurements at 3,6 and 12 months will be performed. These aim to assess the changes from baseline body mass index (BMI) in overweight or obese children, after physical activity and diet interventions. Overweight and obesity are defined using age-specific BMI reference guidelines from the 2000 Centers for Disease Control and Prevention Child Growth Charts. Thus, overweight assumes BMI values between the 85th and 95th percentiles, and obesity implies values above the 95th percentile. |
0,3,6 and 12 months
|
|
Changes from Baseline Systolic Blood Pressure in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial evaluation of systolic blood pressure followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline systolic blood pressure in overweight or obese children, after physical activity and diet interventions. Arterial hypertension is diagnosed as a blood pressure value (systolic, diastolic or both), measured in mmHg, over the 95th percentile for age. |
0,3,6 and 12 months
|
|
Changes from Baseline Diastolic Blood Pressure in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial evaluation of diastolic blood pressure followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline diastolic blood pressure in overweight or obese children after physical activity and diet interventions. Arterial hypertension is diagnosed as a blood pressure value (systolic, diastolic or both), measured in mmHg, over the 95th percentile for age. |
0,3,6 and 12 months
|
|
Evaluation of Changes in Health-Related Quality of Life in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions, using the Pediatric Quality of Life Inventory (PedsQL)
Time Frame: 0,6 and 12 months
|
The questionnaire has 23 items and undertakes the four types of functioning: physical, emotional, social, and educational. It can be filled in by children as well as parents. Higher scores indicate better health-related quality of life. PedsQL will be used at the child's first assessment and reapplied at each control visit. Items on the PedsQL Generic Core Scales are reverse scored and transformed to a 0-100 scale. Higher scores indicate better health related quality of life: 0 ("Never") = 100
|
0,6 and 12 months
|
|
Evaluation of Changes in Individual Self-Esteem in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions, using the Rosenberg self-esteem scale
Time Frame: 0,6 and 12 months
|
This scale is composed of 10 questions and measures positive and negative feelings about the self. The answer range is from strongly agree to strongly disagree. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem. |
0,6 and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ultrasound Evaluation of Changes in Liver Echogenicity in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial ultrasound evaluation of liver echogenicity followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess changes in liver echogenicity and the reduction in hepatic steatosis grade, if diagnosed at onset, in overweight or obese children after physical activity and diet interventions. Non-Alcoholic Fatty Liver Disease (NAFLD) can be diagnosed on ultrasound based on some suggestive parameters: diffuse hyperechoic structure ("bright liver"), deep beam attenuation, liver-to-kidney contrast, bright vessel walls. Non-Alcoholic Fatty Liver Disease (NAFLD) classification:
|
0,3,6 and 12 months
|
|
Ultrasound Evaluation of Changes in Visceral-to-Subcutaneous-Fat Ratio in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial ultrasound measurement of visceral and subcutaneous fat followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess changes in visceral-to-subcutaneous-fat ratio in overweight or obese children after physical activity and diet interventions. Subcutaneous fat thickness (ScFT) is defined as the measurement from the skin-fat interface to the anterior aspect of the linea alba. Visceral fat thickness (VFT) is defined as the thickness from the linea alba to the anterior wall of the aorta. |
0,3,6 and 12 months
|
|
Changes of Carotid Intima-Media Thickness (CIMT) in Children diagnosed with Overweight or Obesity after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial ultrasound measurement of the carotid intima-media thickness (CIMT) followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess changes in carotid intima-media thickness in overweight or obese children after physical activity and diet interventions. At every visit four measurements of CIMT at far wall of the common carotid artery, approximately 1 cm proximal to the bulb, in the end-diastolic phase (2 for the left and 2 for the right CCA) will be obtained. |
0,3,6 and 12 months
|
|
Changes from Baseline Serum Glucose Levels in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial evaluation of glucose levels followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline serum glucose levels in overweight or obese children after physical activity and diet interventions. Impaired glucose metabolism is defined as serum insulin levels over 15 mU/L or fasting blood glucose levels higher than 6.11 mmol/L. |
0,3,6 and 12 months
|
|
Changes from Baseline Serum Lipid Levels in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial evaluation of serum lipid levels followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline serum lipid levels in overweight or obese children after physical activity and diet interventions. Dyslipidemia is defined if triglyceride or total cholesterol levels exceed the 95th percentile for age and sex or if or high-density lipoprotein (HDL) cholesterol levels are below the 5th percentile for age and sex. |
0,3,6 and 12 months
|
|
Changes from Baseline Liver Function Tests in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Liver function will be assessed by determining serum levels of alanine aminotransferase (ALT or TGP) (U/L) and gamma glutamyl transferase (GGT) (U/L) at the initial evaluation, and again at 3, 6 and 12 months.
The aim is to assess the changes from baseline ALT and GGT levels in overweight or obese children after physical activity and diet interventions.
|
0,3,6 and 12 months
|
|
Changes from Baseline Serum Insulin Levels in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial evaluation of serum insulin levels followed by three reevaluations at 3,6 and 12 months will be performed. These aim to assess the changes from baseline serum insulin levels in overweight or obese children after physical activity and diet interventions. In this study, IR will be evaluated by using the homeostasis model assessment for IR index (HOMA - IR), calculated using the following equation: HOMA - IR = fasting insulin (uU/mL) x fasting plasma glucose (mmol/L)/22.5. IR is diagnosed in a patient if HOMA-IR exceeds the 95th percentile for age and sex. |
0,3,6 and 12 months
|
|
Changes from Baseline Inflammatory and Oxidative Stress Markers in Overweight or Obese Children after Physical Activity and Diet Interventions
Time Frame: 0,3,6 and 12 months
|
Initial evaluation of inflammation and oxidative stress status by determining the serum levels of ultrasensitive C-reactive protein (ng/mL), leptin (ng/mL), adiponectin (ng/mL), selenium (μg/L) and glutathione peroxidase (GPx) (U/L).
These parameters will be reevaluated at 3,6 and 12 months to assess the changes from baseline levels in overweight or obese children after physical activity and diet interventions.
|
0,3,6 and 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Teofana O Bizerea-Moga, MD PhD, Neoped - Centru de Pediatrie; "Victor Babeș" University of Medicine and Pharmacy Timișoara, Romania
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Disease
- Liver Diseases
- Overnutrition
- Nutrition Disorders
- Body Weight
- Insulin Resistance
- Hyperinsulinism
- Obesity
- Syndrome
- Fatty Liver
- Metabolic Syndrome
- Pediatric Obesity
- Overweight
- Non-alcoholic Fatty Liver Disease
- Atherosclerosis
Other Study ID Numbers
- 01:Cardio_MetS_Ob
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Spanish National Research CouncilNot yet recruitingAtherosclerosis Cardiovascular DiseaseSpain
-
Nantes University HospitalUniversité de Nantes; French Interregional Group of Clinical Research and Innovation and other collaboratorsNot yet recruitingAtherosclerosis Cardiovascular Disease | Periodontis
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingSubclinical Atherosclerosis
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonNot yet recruitingPeripheral Arterial Disease | Silent AtherosclerosisUnited Kingdom
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
University of Sao PauloNot yet recruitingAtherosclerosis Cardiovascular Disease
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
Clinical Trials on History and Clinical evaluation
-
Asian Institute of Gastroenterology, IndiaAll India Institute of Medical Sciences, New Delhi; Aalborg University Hospital and other collaboratorsRecruiting
-
Ege UniversityCompletedHeart FailureTurkey
-
Diabetes Foundation, IndiaJohns Hopkins University; National Diabetes Obesity and Cholesterol FoundationRecruiting
-
University Hospital, GhentCompletedKnee Arthrodesis With Intramedullary NailBelgium
-
Centre Hospitalier St AnneCompletedPost-stroke DepressionFrance
-
Universitas Negeri SemarangUniversitas Diponegoro; Ministry of Research, Technology and Higher Education...CompletedTour de Borobudur Troponin Study on Predictors and Synergistic Role of MDA and Hs-CRP Levels (TdBTS)Inflammatory Response | Heart Arrest | Oxidative Stress | Sport InjuryIndonesia
-
Randers Regional HospitalAarhus University HospitalCompleted
-
Fundacion para la Investigacion y Formacion en...Completed
-
University Hospital, ToulouseTerminatedStroke | Muscle Spasticity | Upper Extremity ParalysisFrance
-
Johns Hopkins UniversityNeurofibromatosis Therapeutic Acceleration ProgramActive, not recruitingNeurofibromatosis 1 | Neurofibromatosis Type 1 | Cutaneous Neurofibroma | Neurofibromatosis (Nonmalignant)United States